I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
Italian Journal of Pediatrics volume 38, Article number: 53 (2012)
Iodine-131-metaiodiobenzylguanidine (131I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. Although 131I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. Based on our findings, we suggest that 131I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible.
Neuroblastoma is the most common extracranial solid tumor of childhood. Although dose-intensive treatments have improved the prognosis of patients with advanced neuroblastoma, the prognosis of this disease remains very poor, and the survival rate is estimated to be 25%. Myeloablative allogeneic stem cell transplantation (SCT) rescue has not been extensively used to treat neuroblastoma, primarily because of the toxicity of megatherapy regimens and the risk of graft-versus-host disease (GVHD)[2, 3].
Recent reports have described the use of iodine-131-metaiodiobenzylguanidine (131I-MIBG) treatment combined with autologous SCT rescue in patients with recurrent neuroblastoma; however, this treatment does not always yield satisfactory results[4, 5].
The subject was a 2-year-old female with a diagnosis of stage 4 neuroblastoma with unfavorable histology according to the international neuroblastoma pathology classification, non-amplification of MYCN, and primary localization to the left adrenal gland with metastasis to the thoracic vertebrae, pelvis, and bone marrow. Vanillylmandelic acid (VMA) was elevated to 448.2 μg/mg creatinine (Cr) and homovanillic acid (HVA) was increased to 127.8 μg/mg Cr. The patient was treated with chemotherapeutic drugs (cyclophosphamide, vincristine, therarubicin, and cisplatin), irradiation of the abdominal cavity, and surgical resection of the adrenal gland, followed by autologous peripheral blood stem cell transplantation (PBSCT). After treatment, VMA and HVA were normalized to 2.4 and 4.6 μg/mg Cr, respectively, and 123I-MIBG accumulation was not detected by scintigraphy.
The recurrence, which presented with multiple metastases in the bone marrow, occurred 2 years after PBSCT (Figure1A). At this time, VAM and HVA had increased to 273.5 and 87.7 μg/mg Cr, respectively. After 4 cycles of chemotherapy with topotecan and etoposide, 131I-MIBG treatment was performed at a dose of 18 mCi/kg. We decided to perform cord blood stem cell transplantation (CBSCT) for hematopoietic rescue after the myeloablative therapies.
After injection of 131I-MIBG (18 mCi/kg), the patient was isolated in a shielded room for 7 days. Nine days after 131I-MIBG infusion, the patient was treated with busulfan (1.1 mg/kg/day, 4 times daily on days −8 to −5) and melphalan (90 mg/m2/day, once daily, on days −4 and −3) before cord blood stem cells with one HLA-DR locus mismatch were transfused. Cyclosporine-A and methylprednisolone were administered as a prophylaxis against acute GVHD. Although the patient developed grade II acute GVHD with skin erythema which was controlled additional predonisolone, no other significant complications occurred. The patient’s neutrophil count was >500 /μl at 26 days and the platelet count was >20,000 /μl at 35 days after CBSCT. VMA and HVA were normalized to 22.6 and 10.1 μg/mg Cr, respectively. 123I-MIBG accumulation was significantly decreased in parietal bone and humerus (Figure1, black arrows); however, 123I-MIBG was still detected in the thoracic vertebrae and femur after CBSCT (Figure1B, white arrows). Unfortunately, the patient died 12 months after CBSCT, even though VAM and HVA were within the normal ranges for 5 months.
Because MIBG is selectively concentrated in sympathetic nervous tissue, 131I-MIBG tends to accumulate in neuroblastoma cells[4, 5]. Thus, 131I-MIBG is potentially capable of selectively delivering a substantial radiation dose to neoplastic cells while sparing normal tissues. In our patient, the number of residual neuroblastoma cells decreased after 131I-MIBG treatment and CBSCT.
Allo-SCT for the treatment of neuroblastoma is considered an alternative method when autologous stem cells cannot be harvested in sufficient quantity. The superiority of allo-SCT to auto-SCT has not been clearly demonstrated[4, 7], although some studies have reported a graft-versus-tumor (GVT) effect in patients with advanced neuroblastoma[7, 8]. We believe that although 131I-MIBG treatment combined with allo-CBSCT megatherapy did not induce complete remission, the normalization of VMA and HVA, which lasted for 5 months, and the prolonged survival for 12 months were due to the reduction of neuroblastoma cells by 131I-MIBG treatment together with a GVT effect.
Our patient experienced relapse in the bone marrow 2 years after auto-PBSCT, suggesting that some minimal residual disease remained, even though VMA and HVA were within normal ranges, and the accumulation of 123I-MIBG was not observed. Chemotherapy alone has been reported to yield unsatisfactory results when used to target neuroblastoma cells in the bone marrow[9, 10]. Thus, complete elimination of minimal residual neuroblastoma is an important therapeutic goal. 131I-MIBG and GVT could target neuroblastoma cells by different mechanisms; therefore, they could be synergistically effective against minimal residual disease. Based on our experience with this patient, we propose that 131I-MIBG treatment combined with allo-SCT may be an effective first-line therapy for high-risk neuroblastoma (Stage 4 or MYCN amplification); however, the cost and availability of equipment to perform 131I-MIBG treatment may be prohibitive for some institutions.
Treatment of 131I-MIBG with allo-SCT was effective and safe for high-risk neuroblastoma.
Written informed consent was obtained from the parents of the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002, 24: 613-621. 10.1097/00043426-200211000-00004.
Hirayama M, Azuma E, Araki M, Komada Y, Nakagawa A: Evidence of graft-versus-tumor effect in refractory metastatic neuroblastoma. Transplantation. 2006, 82: 142-144.
Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, Selch M, Atkinson JB, Haase GM, Ramsay NK: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma. a report from the Childrens Cancer Group. 1994, 12: 2382-2389.
de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN: Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer. 2008, 44: 551-556. 10.1016/j.ejca.2008.01.010.
Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM: Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007, 25: 1054-1060. 10.1200/JCO.2006.09.3484.
Molina B, Alonso L, Gonzalez-Vicent M, Andion M, Hernandez C, Lassaletta A, Cormenzana M, Lopez-Ibor B, Villa M, Molina J, Diaz MA: High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients. Pediatr Hematol Oncol. 2011, 28: 115-123. 10.3109/08880018.2010.537434.
Goi K, Inukai T, Honna H, Akahane K, Hirose K, Kuroda I, Hasuda N, Koshizuka K, Takano K, Sugita K: Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN. Bone Marrow Transplant. 2011, 46: 835-839. 10.1038/bmt.2010.191.
Takahashi H, Manabe A, Aoyama C, Kamiya T, Kato I, Takusagawa A, Ogawa C, Ozawa M, Hosoya R, Yokoyama K: Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma. Pediatr Blood Cancer. 2008, 50: 676-8.9. 10.1002/pbc.21126.
Fukuda M, Miyajima Y, Miyashita Y, Horibe K: Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol. 2001, 23: 10-13. 10.1097/00043426-200101000-00004.
Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y: Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol. 2001, 36: 203-204. 10.1002/1096-911X(20010101)36:1<203::AID-MPO1049>3.0.CO;2-T.
The authors declare that they have no competing interests.
All authors have equally participated in drafting of the manuscript and/or critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Sato, Y., Kurosawa, H., Fukushima, K. et al. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma. Ital J Pediatr 38, 53 (2012). https://doi.org/10.1186/1824-7288-38-53